Powder: -20°C for 3 years | In solvent: -80°C for 1 year
R-7050 (TNF-α Antagonist III) 是一种肿瘤坏死因子受体拮抗剂,对 TNFα具有更高选择性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 278 | 现货 | ||
2 mg | ¥ 392 | 现货 | ||
5 mg | ¥ 598 | 现货 | ||
10 mg | ¥ 866 | 现货 | ||
25 mg | ¥ 1,960 | 现货 | ||
50 mg | ¥ 2,980 | 现货 | ||
100 mg | ¥ 4,290 | 现货 | ||
500 mg | ¥ 8,880 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 663 | 现货 |
产品描述 | R-7050 (TNF-α Antagonist III), a tumor necrosis factor receptor (TNFR) antagonist, exhibits heightened selectivity for TNFα. |
体外活性 | R-7050 is a cell-permeable triazoloquinoxaline compound that selectively inhibits TNF-α induced cellular signaling. Unlike biologic TNF inhibitors (e.g. Infliximab, Etanercept, Adalimumab) that directly bind TNF-α and function as decoy receptors, R-7050 does not affect binding of TNF-α to TNFR. In contrast, R-7050 selectively inhibits the association of TNFR with intracellular adaptor molecules (e.g. TRADD, RIP), limits receptor internalization, and prevents subsequent cellular responses after TNF-α binding[2]. |
体内活性 | R-7050 (6 mg/kg) reduces Evans blue extravasation to 28.7±5.9 μg and 30.3±1.9 μg Evans blue/g brain tissue when administered at 0.5 h or 2 h post-ICH, respectively (p<0.05 and p<0.01 vs ICH, respectively; not significantly different from sham). Brain water content which is a measure of brain edema increases from 75.6±0.3% in sham-operated mice to 81.5±0.5% at 24h post-ICH (p<0.05 vs. sham). 6, 12, or 18 mg/kg R-7050 reduces brain water content to 78.5±0.3%, 78.3±0.3%, or 79.3±0.5%, respectively (all treatments p<0.05 vs. ICH; treatments not significantly different from each other). Notably, mice treated with 18 mg/kg exhibit a reduction in general activity/locomotion. As is observed with Evans blue extravasation, R-7050 (6 mg/kg) significantly reduces brain water content after ICH. Administration of R-7050 at 0.5h or 2h post-ICH attenuates brain water content to levels observed in sham-operated mice (p<0.05 vs ICH, not significantly different from sham)[2]. |
别名 | TNF-α Antagonist III |
分子量 | 380.77 |
分子式 | C16H8ClF3N4S |
CAS No. | 303997-35-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mg/mL (26.26 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.6263 mL | 13.1313 mL | 26.2626 mL | 65.6564 mL |
5 mM | 0.5253 mL | 2.6263 mL | 5.2525 mL | 13.1313 mL | |
10 mM | 0.2626 mL | 1.3131 mL | 2.6263 mL | 6.5656 mL | |
20 mM | 0.1313 mL | 0.6566 mL | 1.3131 mL | 3.2828 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
R-7050 303997-35-5 Apoptosis TNF Inhibitor TNF-a Antagonist III inhibit TNFR Tumor Necrosis Factor Receptor TNF Receptor TNF-α Antagonist III R7050 R 7050 TNF-alpha Antagonist III inhibitor